Zh Vopr Neirokhir Im N N Burdenko
[Article in Russian]
Elinskii MP, Rafikov AM, Kesaev SA
Experience in the use of Hyperbaric Oxygenation
(HBO) in 56 neurosurgical patients with cerebral vascular aneurysms,
mainly in the postoperative period, testifies to the expediency of
including this method in the complex of therapeutic measures for
these patients. The deep oxygenation of the body tissues, the brain
included, produced by HBO makes it possible to prevent in many cases
the development of severe and stable neurological defects in the
postoperative period and contributes to the normalization of vitally
important functions. The therapeutic efficacy of the method is more
marked when it is applied sufficiently early (before poorly
reparable secondary disorders occur in the organism).
HBOT and Neurological conditions.
Dr.Pierre Marois’s abstract.
International Congress on Hyperbaric Medicine
October 2nd 2002
San Francisco, Ca
Subject: HBOT and neurological conditions.
Dr.Pierre Marois’s abstract.
The results of the sole double blind study on
the use of Hyperbaric Oxygen Therapy (HBOT) in the treatment of
cerebral palsy were published last year in “ The Lancet”. Although
the results show substantial and long-term improvements in gross
motor function, speech, attention, memory and functional skills,
there has been controversy in the interpretation of the causes of
these changes. The Government of Quebec and some scientists have
chosen to believe that the improvements observed in both groups of
children (one treated at 1.3ATA, 21%O2, and the other at 1.75 ATA,
100%O2) were due solely to a placebo effect. Unfortunately, this was
the conclusion that was presented at the “The American Academy of
Developmental Medicine and Cerebral Palsy” meeting in September 2000
in Toronto, Canada. Most of the main researchers involved in the
study believe that the cause of these improvements were not clearly
identified and postulate that both treatments could have been
equally effective. In fact, the changes that were seen in this
research were greater, more generalized and obtained in a shorter
period of time than most of the improvements measured with any other
recognized conventional therapy in the treatment of cerebral palsy
including: intensive physical therapy, rhizotomy, Botox injections
The studies done using HBOT to treat C.P. have
all shown significant improvements. The 5 recent pilot studies
(McGill, Galveston, Cornell, U.S. Army and the Cuban study), the
Machado study and the Quebec double blind study have indicated that
most of the 400 children evaluated improved significantly.
Furthermore, there are more than a thousand anecdotal reports of
changes and hundreds of measured improvements that have been
documented and described worldwide. There is not a single study that
has ever denied these positive effects.
So far, among the numerous research projects
conducted in treatment of C.P. there is not a single one that has
ever showed a placebo or participation effect. A consistently
reproducible and permanent placebo effect has never been documented
in any condition, and certainly not with results superior to those
obtained with recognized therapies for a given condition.
Hyperbaric oxygen therapy at 1.3 ATA is not by
any means a placebo treatment, the effects of the increase in
pressure also increases the amount of oxygen dissolved in body
tissue by more than 50%. There is an increasing amount of evidence
that is demonstrating that low pressure hyperbaric treatment induces
permanent changes in a damaged brain. The studies of Dr Heuser at
U.C.L.A. and experiences with thousands of cases in Russia, as well
as some studies in humans and rats are suggesting that HBOT even at
a pressure as low as 1.1 ATA is effective in improving functional
skills and SPECT scan imaging.
HBOT is used and recognized for the treatment
of many medical conditions. The recognition of its clinical
indication has often been based on less scientific evidence and
studies than in the case of C.P. and other neurological
How much more evidence will it take?
The pursuit of research on HBOT in the
treatment in C.P. is essential to better define the indications, the
dosage, and to understand the underlying mechanisms behind all the
impressive changes observed in thousands of patients.
Dr.Pierre Marois M.D